Psilocybin - MycoMedia Life Sciences
Alternative Names: MLS 101 - MycoMedia Life Sciences; MLS-101 - MycoMedica Life SciencesLatest Information Update: 18 Dec 2024
Price :
$50 *
At a glance
- Originator MycoMedica Life Sciences
- Class Antipsychotics; Neuroprotectants; Neuropsychotherapeutics
- Mechanism of Action Serotonin 5-HT2A receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Psychiatric disorders
Most Recent Events
- 08 Nov 2024 MycoMedica Life Sciences initiates a phase I trial in Psychiatric disorders (In volunteers) in Australia (PO) (NCT06643637)
- 01 Mar 2024 Phase-I clinical trials in Psychiatric disorders (In volunteers) in Australia (PO) (NCT06326606)